Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma.

Human malignant gliomas are highly lethal neoplasms. Involved-field radiotherapy is the most important therapeutic measure. Most relapses originate from the close vicinity of the irradiated target field. Here, we report that sublethal doses of irradiation enhance the migration and invasiveness of human malignant glioma cells. This hitherto unknown biological effect of irradiation is p53 independent, involves enhanced alphavbeta3 integrin expression, an altered profile of matrix metalloproteinase-2 and matrix metalloproteinase-9 (MMP-2 and MMP-9) expression and activity, altered membrane type 1 MMP and tissue inhibitor of metalloproteinases-2 expression, and an altered BCL-2/BAX rheostat favoring resistance to apoptosis. BCL-2 gene transfer and irradiation cooperate to enhance migration and invasiveness in a synergistic manner. Sublethal irradiation of rat 9L glioma cells results in the formation of a greater number of tumor satellites in the rat brain in vivo concomitant with enhanced MMP-2 and reduced tissue inhibitor of metalloproteinases-2 expression. Collectively, these data suggest that the current concepts of involved-field radiotherapy for malignant glioma need to be reconsidered and that the pharmacological inhibition of migration and invasion during radiotherapy may represent a new therapeutic approach to improve the therapeutic efficacy of radiotherapy for malignant glioma.

[1]  Erwin G. Van Meir,et al.  Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.

[2]  P. Wen,et al.  Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. , 1990, International journal of radiation oncology, biology, physics.

[3]  M. Schwab,et al.  Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity. , 1998, Cancer research.

[4]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[5]  W. Stetler-Stevenson,et al.  Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. , 1996, Cell.

[6]  K. Wallner,et al.  Patterns of second recurrence of malignant astrocytomas. , 1990, International journal of radiation oncology, biology, physics.

[7]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[8]  J. Dichgans,et al.  Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. , 2000, Biochemical and biophysical research communications.

[9]  C. Gladson,et al.  Ligation of Integrin α5β1 Is Required for Internalization of Vitronectin by Integrin αvβ3* , 1997, The Journal of Biological Chemistry.

[10]  U. Lendahl,et al.  Expression of the class VI intermediate filament nestin in human central nervous system tumors. , 1992, Cancer research.

[11]  S. Hockfield,et al.  Expression of a Cleaved Brain-Specific Extracellular Matrix Protein Mediates Glioma Cell Invasion In Vivo , 1998, The Journal of Neuroscience.

[12]  J. Dichgans,et al.  BCL‐2 promotes migration and invasiveness of human glioma cells , 1998, FEBS letters.

[13]  M. Weller,et al.  Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. , 1999, Experimental cell research.

[14]  J. Dichgans,et al.  BCL-2 Family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy , 1999, Journal of neurology, neurosurgery, and psychiatry.

[15]  C. Hess,et al.  Malignant glioma: patterns of failure following individually tailored limited volume irradiation. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  J. Dichgans,et al.  Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses , 1998, International journal of cancer.

[17]  R. Bjerkvig,et al.  Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain. , 1993, Cancer research.

[18]  Y. Sun,et al.  Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter , 1997, Molecular and cellular biology.

[19]  R. Brown,et al.  Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. , 1998, British Journal of Cancer.

[20]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[21]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[22]  M. Weller,et al.  Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. , 1995, The Journal of clinical investigation.

[23]  J. Calvete,et al.  Structural Requirements of Echistatin for the Recognition of αvβ3 and α5β1Integrins* , 1999, The Journal of Biological Chemistry.

[24]  John Calvin Reed Double identity for proteins of the Bcl-2 family , 1997, Nature.

[25]  W. Yung,et al.  Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  F. Mornex,et al.  Radiation Therapy for Malignant Astrocytomas in Adults , 1994 .

[27]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[28]  Kristiina Vuori,et al.  Integrin Activation by R-ras , 1996, Cell.